Whole‐exome sequencing identified ARL2 as a novel candidate gene for MRCS (microcornea, rod‐cone dystrophy, cataract, and posterior staphyloma) syndrome.

MLA

Cai, Xue‐Bi, et al. “Whole‐exome Sequencing Identified ARL2 as a Novel Candidate Gene for MRCS (Microcornea, Rod‐cone Dystrophy, Cataract, and Posterior Staphyloma) Syndrome.” Clinical Genetics, vol. 96, no. 1, July 2019, pp. 61–71. EBSCOhost, https://doi.org/10.1111/cge.13541.

APA

Cai, X., Wu, K., Zhang, X., Lv, J., Jin, G., Xiang, L., Chen, J., Huang, X., Pan, D., Lu, B., Lu, F., Qu, J., & Jin, Z. (2019). Whole‐exome sequencing identified ARL2 as a novel candidate gene for MRCS (microcornea, rod‐cone dystrophy, cataract, and posterior staphyloma) syndrome. Clinical Genetics, 96(1), 61–71. https://doi.org/10.1111/cge.13541

Chicago

Cai, Xue‐Bi, Kun‐Chao Wu, Xiao Zhang, Ji‐Neng Lv, Guang‐Hui Jin, Lue Xiang, Jie Chen, et al. 2019. “Whole‐exome Sequencing Identified ARL2 as a Novel Candidate Gene for MRCS (Microcornea, Rod‐cone Dystrophy, Cataract, and Posterior Staphyloma) Syndrome.” Clinical Genetics 96 (1): 61–71. doi:10.1111/cge.13541.